| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review |
| 30 Sep 2026 |
8-K: Other Events
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years |
| 16 Jul 2026 |
8-K: Results of Operations and Financial Condition
Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026 |
| 29 Jun 2026 |
8-K: Other Events
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
| 03 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
The Company was incorporated in the form of a French Limited Company (Société Anonyme) with a Board of Directors. |
| 05 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 30, 2026 the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”), upon recommendation of the Compensation Committee (the “Committee”) of the Board, approved the DBV Technologies 2026 Performance Share Unit ... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement (“PIPE... |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) |
| 02 Mar 2026 |
8-K: Other Events
Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group |
| 20 Jan 2026 |
8-K: Other Events
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing |
| 16 Dec 2025 |
8-K: Other Events
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years |
| 30 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee... |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition
DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 |
| 18 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (t... |
| 05 Sep 2025 |
8-K: Other Events
DBV Technologies S.A., a société anonyme formed under the laws of France, having its registered office at 107 avenue de la République, 92320 Châtillon, France, and registered with the registre du commerce et des sociétés of Nanterre unde... |
| 29 Jul 2025 |
8-K: Results of Operations and Financial Condition
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-yea... |
| 25 Jun 2025 |
8-K: Other Events
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old |
| 11 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
The Company was incorporated in the form of a French Limited Company (Société Anonyme) with a Board of Directors. |
| 30 Apr 2025 |
8-K: Results of Operations and Financial Condition
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three mon... |
Loading...